Article, News
Three life sciences stocks that may be undervalued
Life science stocks have suffered heavily in 2022 due to investors shifting out of risk assets, resulting in a bear market for biotech and medical…
Article, News
ASX Quarterly Wrap: Growing pipeline, milestones, and bullish guidance were the themes for these stocks
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with update lodgements. To save you the trouble of trudging through…
Article, News
Aussie biotech presents CAR-T platforms at prestigious global conference
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has just presented at the Cell & Gene Meeting on the Mediterranean, after being invited to present…
Article, News
Health Kick Podcast: Prescient Therapeutics’ PTX-100 continues to show encouraging results following FDA Orphan Drug Designation
Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast….
Article, News
Cancer cure no longer science fiction: Prescient boss
Cell and gene therapy is changing the game when it comes to cancer treatment and it’s closing in on possibly finding a cure, says ASX-listed…
Article, News
Prescient Therapeutics hopes to accelerate bid for US FDA study approval for targeted therapy PTX-100
Prescient Therapeutics is hoping to follow in the footsteps of Neuren Pharmaceuticals after positive results from its latest Phase 1b clinical trial. Prescient Therapeutics (ASX:PTX) will…
Article, News
Prescient Therapeutics furthers development of novel anti-cancer targeted therapies
Prescient Therapeutics (ASX: PTX) managing director and chief executive officer Steven Yatomi-Clarke joins Small Caps to discuss the company’s development activities and plans for its…
Article, News
ASX Health Stocks: High fives as Telix gets expanded FDA approval, Prescient’s PTX-100 returns good results
Telix Pharma (ASX:TLX) announced the US FDA has approved a supplementary New Drug Application (sNDA) for Illuccix, a kit for the preparation of gallium Ga 68 gozetotide…
Article, News
Prescient (ASX:PTX) reports promising clinical data for PTX-100 in relapsed and refractory TCL – Kalkine Media
Prescient Therapeutics Limited (ASX:PTX) has shared an encouraging update for the ongoing clinical trial of its PTX-100 compound in patients with relapsed and refractory T…